Chinese inhibitor drug candidate becomes first to enter phase
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
Confidence of US consumers continues to decline as Americans worry about the future
WASHINGTON (AP) — U.S. consumer confidence deteriorated for the third straight month as Americans co2024-05-01Xiplomacy: China's Vision of Global Governance for Addressing Common Challenges
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01Xi Meets German Chancellor Olaf Scholz
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01Xi Sends Condolences to Indian President, PM over Bridge Collapse
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01Dua Lipa is all about 'Radical Optimism,' in her music and other pursuits
NEW YORK (AP) — Dua Lipa is floating in the ocean, the sun just beginning to set behind her. She loo2024-05-01Xi Sends Congratulations to Gala Dinner of National Committee on U.S.
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-01
atest comment